 |
|
|
|
January 1999 Cover
|
|
A recent study indicates that oral imiquimod, an immune response modifier, may be useful in the treatment of HIV. Researchers conducted a phase I trial of the
drug in 12 asymptomatic HIV-infected adults. Previous research suggests that IFN-alpha therapy has positive effects on HIV patients with Kaposi's sarcoma and could
slow HIV progression in those in the early phases of infection. The researchers here note that all subjects experienced biologic responses to the drug at doses of 200 mg
or more, and they suggest that interferon inducers, such as oral imiquimod, may be useful in future combination therapies against HIV.
Editor's Note: from Journal of Infectious Diseases
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
